Stereotaxis’ RMN technology is a system designed for cardiac ablation procedures in arrhythmia treatment. Credit: mi_viri via Shutterstock.

Patients at the University of Kansas Health System in the US have been successfully treated with Stereotaxis’ endovascular robotic system.

Missouri-based Stereotaxis is expanding its market presence with the Genesis robotic magnetic navigation (RMN) system through a partnership with the healthcare provider.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The technology – which is used to treat patients with arrhythmias or abnormal heart rhythms – has already been used in the treatment of over 150,000 patients worldwide, according to the company. Physicians at Baptist Health Lexington, a hospital in Kentucky, performed the first procedures with the Genesis surgical robotic system in November 2023.

Stereotaxis’ RMN technology is a system designed for cardiac ablation procedures in arrhythmia treatment. It incorporates compact magnets that rotate along the centre of mass to respond to physician input. As per the company, the smaller size of the system aims for more efficient use of lab space and to improve patient access and comfort.

Seth Sheldon, cardiac electrophysiologist at the University of Kansas health system, said: “The robotic precision and stability offered by the Genesis System allows us to deliver precise, personalised treatments to our patients, ultimately improving outcomes and quality of life.”

Stereotaxis reached a breakthrough in August 2024 when it submitted its next-generation robot system GenesisX to the US Food and Drug Administration (FDA), following the receipt of a CE mark in Europe. The GenesisX system is the latest iteration of Stereotaxis’ Genesis RMN system, which is 80% smaller than the previous generation of Genesis. Stereotaxis hopes for a full US launch and adoption next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In May 2023, Stereotaxis and Abbott teamed up to integrate Abbott’s EnSite X EP system with Stereotaxis’ RMN systems. Abbott’s system secured FDA clearance in 2022 and is designed to create detailed 3D maps of the heart that allow surgeons to identify and treat areas where arrhythmias originate. The global market for robotic surgical systems and their accessories will reach $10bn by the end of this year and $15.8bn by 2030, according to GlobalData analysis.

Elsewhere in the arrhythmia device space, UK wearable device company Ultrahuman launched an atrial fibrillation (AFib) detection feature to its Ring AIR smart ring in July 2024. As part of the AFib detection, the device monitors an individual’s heart rhythm nightly, powered by FDA-cleared FibriCheck technology.